Cancer chemotherapy and pharmacology
-
Cancer Chemother. Pharmacol. · May 2010
Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
The folate receptor (FR) is overexpressed in a broad spectrum of malignant tumors and represents an attractive target for selective delivery of anti-cancer agents to FR-expressing tumors. Targeting liposomes to the FR has been proposed as a way to enhance the effects of liposome-based chemotherapy. ⋯ Folate-targeting confers a significant albeit modest therapeutic improvement to PLD in FR-expressing tumor models, which appears particularly valuable in intracavitary therapy. The potential clinical added value of this approach has yet to be determined.